| Name | Title | Contact Details |
|---|
Nexxess International is a National Private Trust Management Company, located near Dallas, TX. Today, Nexxess has more than 200 consulting partners and we manage wealth and trusts for clients. As a leader in complex trust structuring, Nexxess can help both clients, large or small. We have staff of many different skill sets, including Financial Planners, Enrolled Agents, CPAs, Attorneys and more.
Modernizing and simplifying the landscape design and install process. Locally owned and operated in Woodbury, Minnesota. We are the catalyst for your outdoor dream space. OUR STORY Locally established here by 4 high school athletes in 2016. Passionate about making a positive impact in our community. Our expertise, quality, and reliability have helped us continue to grow and serve the residents and businesses of Eastside Twin Cities. Check out our website below for a full list of our services!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
MGT is a national technology and advisory solutions leader serving state, local government, education (SLED) and targeted commercial clients. Our specialized solutions solve the most critical issues that live at the top of our clients leadership agenda. We partner to help clients build resilience, implement systematic change and strengthen their foundations, now and for the future. MGT is committed to impacting communities for good. For more information, visit us at mgt.us.